Cytokinetics (CYTK) Non-Current Deffered Revenue (2016 - 2022)
Historic Non-Current Deffered Revenue for Cytokinetics (CYTK) over the last 9 years, with Q1 2022 value amounting to $87.0 million.
- Cytokinetics' Non-Current Deffered Revenue changed 0.0% to $87.0 million in Q1 2022 from the same period last year, while for Mar 2022 it was $87.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $87.0 million for FY2021, which is 0.0% changed from last year.
- As of Q1 2022, Cytokinetics' Non-Current Deffered Revenue stood at $87.0 million, which was down 0.0% from $87.0 million recorded in Q4 2021.
- Cytokinetics' 5-year Non-Current Deffered Revenue high stood at $87.0 million for Q4 2020, and its period low was $87.0 million during Q4 2020.
- In the last 3 years, Cytokinetics' Non-Current Deffered Revenue had a median value of $87.0 million in 2020 and averaged $87.0 million.
- Over the last 5 years, Cytokinetics' Non-Current Deffered Revenue had its largest YoY gain of 0.0% in 2021, and its largest YoY loss of 0.0% in 2021.
- Quarter analysis of 3 years shows Cytokinetics' Non-Current Deffered Revenue stood at $87.0 million in 2020, then changed by 0.0% to $87.0 million in 2021, then changed by 0.0% to $87.0 million in 2022.
- Its Non-Current Deffered Revenue was $87.0 million in Q1 2022, compared to $87.0 million in Q4 2021 and $87.0 million in Q3 2021.